Acasti Pharma (FRA:A1P0) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Acasti Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Acasti Pharma's Free Cash Flow for the three months ended in Dec. 2023 was €-1.74 Mil. Acasti Pharma's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Acasti Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Acasti Pharma's current FCF Yield % is -53.71%.

The historical rank and industry rank for Acasti Pharma's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Acasti Pharma was -366.48%. The lowest was -7340.82%. And the median was -1388.89%.

FRA:A1P0's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144.01
* Ranked among companies with meaningful FCF Margin % only.

Acasti Pharma FCF Margin % Historical Data

The historical data trend for Acasti Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma FCF Margin % Chart

Acasti Pharma Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-7,324.85

Acasti Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Acasti Pharma's FCF Margin %

For the Biotechnology subindustry, Acasti Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acasti Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's FCF Margin % falls into.

Acasti Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Acasti Pharma's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-14.879	/	0
	=	%

Acasti Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.735	/	0
	=	%

Acasti Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (FRA:A1P0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (FRA:A1P0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ACST:USA A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Acasti Pharma (FRA:A1P0) Headlines

No Headlines